Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9Y5X0

UPID:
SNX10_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q9Y5X0; E9PFH5; Q8IYT5

BACKGROUND:
The protein Sorting nexin-10, with its significant function in endosomal protein sorting and membrane trafficking, is essential for the proper localization of proteins to the cilium. It ensures the transport of crucial components like V-ATPase subunits and RAB8A, playing a key role in cilium biogenesis and osteoclast differentiation.

THERAPEUTIC SIGNIFICANCE:
Given its critical role in the pathogenesis of Osteopetrosis, autosomal recessive 8, Sorting nexin-10 represents a promising target for therapeutic intervention. The protein's influence on bone resorption and osteoclast differentiation provides a unique opportunity to develop novel treatments for bone density diseases, offering hope for patients suffering from these conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.